Cardiac Science Receives ISO 9002 and CE Certification.

IRVINE, Calif.--(BW HealthWire)--July 8, 1998--Cardiac Science Inc. (OTC/BB:DFIB), developer of the Powerheart(R) Automatic External Cardioverter Defibrillator (AECD(R)) technology, has received certification to the ISO 9002 quality standard as well as the European Union's Medical Devices Directive (MDD).

TUV Product Services served as the company's registrar and Notified Body in conducting the certification audit. MDD certification allows the company to legally affix the CE Marking to offer its products for sale in the European Community and European Economic area. The CE Marking is required for sales into these markets after June 14, 1998.

The ISO 9002 quality standard involves all operational areas of the business including sales, contract management, engineering, manufacturing, quality assurance, test, service, and customer support. Maintaining certification to the ISO 9002 standard requires continuous improvement of processes aimed at achieving total customer satisfaction. Registration to ISO 9002 validates Cardiac Science's conformance with the standards set by the International Organization for Standardization. Over 90 countries around the world have adopted the ISO 9000 series of standards.

"This is a major achievement for Cardiac Science and all of its employees. Without strong employee participation, this could not have happened" said Raymond W. Cohen, president & chief executive officer. "ISO 9002 certification not only provides a significant impetus to our internal operations, but it also is highly recognized in the marketplace, particularly internationally. International customers often require ISO 9000 certification as a precondition to be qualified as a supplier."

Using its proprietary tachyarrhythmia software technology platform, Cardiac Science developed the Powerheart Automatic External Cardioverter Defibrillator. The Powerheart(R), a non-invasive bedside defibrillator used to continuously monitor hospitalized cardiac patients for life-threatening heart rhythms, delivers defibrillation shocks within seconds and without human intervention should a patient suffer cardiac arrest.

The Powerheart AECD(R), in controlled multi-center clinical studies, demonstrated a sensitivity of 100 percent (correctly identifying shockable episodes), a specificity of 99.4 percent (not allowing a non-shockable rhythm to be shocked), first shock efficacy of 96.2 percent with energy levels as low as 50 joules and an average response time of 21 seconds, indicating that it is an accurate and reliable tool in helping to save people from in-hospital cardiac arrest.

Cardiac Science, through its subsidiary Diagnostic Monitoring, manufactures Ambulatory Holter ECG recorders and Holter systems and distributes these products in the United States and in over 40 countries. For more information, visit the company's Web sites at www.cardiacscience.com and www.diagnosticmonitoring.com.

This news release contains forward-looking statements, including but not limited to those regarding Cardiac Science's ability to improve patient-care, increase survival rates for in-hospital cardiac arrest victims, and reduce patient care costs. Actual results could vary materially from the description contained herein due to many factors, including hospital operations, market and clinical users' acceptance of new and existing products, impact of competitive products and pricing, changing market conditions, and risks detailed in the company's Form 10-KSB for the year ending Dec. 31, 1997 and other documents filed with the Securities and Exchange Commission. The company does not undertake any obligation to update the information contained herein, which speaks only as of this date. The Powerheart(R) and AECD(R) are registered trademarks of Cardiac Science Inc.

    CONTACT:  Cardiac Science Inc., Irvine
               Brett Scott, Chief Financial Officer
               Stan Tillman, Director of Quality Assurance &
               Regulatory Affairs
               949/587-0357